Important lessons have been learned in the use of injectable PLLA that have helped reduce the frequency of adverse events and make it desirable for restoring facial volume (Table 1). The importance of diffuse distribution of the injectable PLLA suspension
Poly-L-lactic acid (PLLA) was approved for use in Europe in 1999. In the United States, it was approved by the Food and Drug Administration in 2004 for the treatment of facial lipoatrophy associated with human immunodeficiency virus, and in 2009 for cosm
This study demonstrated, in real-life conditions and on a large sample, that PLLA injections were feasible, efficient, and safe when performed by trained physicians.
